Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Adma Biologics
(NQ:
ADMA
)
21.18
-0.12 (-0.56%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Adma Biologics
< Previous
1
2
3
4
5
6
Next >
BioNTech Stock Got A IBD RS Rating Lift
November 14, 2024
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Via
Investor's Business Daily
While growth is established for NASDAQ:ADMA, the stock's valuation remains reasonable.
November 12, 2024
For those who appreciate growth without the sticker shock, NASDAQ:ADMA is worth considering.
Via
Chartmill
Vericel Stock Sees RS Rating Shoot Higher
November 11, 2024
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Via
Investor's Business Daily
Buckle Up And Use Volitility To Your Advantage
November 03, 2024
The Advance/Decline trend on the NYSE weakened; the Nasdaq A/D line is outright scary.
Via
Talk Markets
What You Missed On Wall Street This Past Friday
November 03, 2024
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via
Talk Markets
(ADMA) - Analyzing ADMA Biologics's Short Interest
October 22, 2024
Via
Benzinga
Key Takeaways From ADMA Biologics Analyst Ratings
October 14, 2024
Via
Benzinga
This Is What Whales Are Betting On ADMA Biologics
October 10, 2024
Via
Benzinga
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
November 01, 2024
Via
Benzinga
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle
November 01, 2024
The company signed on a new accounting firm less than a month after its previous accountant resigned unexpectedly.
Via
Investor's Business Daily
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
October 15, 2024
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January.
Via
Investor's Business Daily
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
October 14, 2024
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
Via
Investor's Business Daily
IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns
October 10, 2024
The company reiterated its outlook for 2024 and 2025.
Via
Investor's Business Daily
Exploring high growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA).
October 08, 2024
Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock.
Via
Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.
September 24, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.
Via
Chartmill
In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics
September 20, 2024
Via
Benzinga
CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter
October 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 10, 2024
Via
Benzinga
What's Going On With ADMA Biologics Stock Monday?
September 09, 2024
ADMA Biologics shares are moving higher after it was announced that the company will join the S&P SmallCap 600.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
September 09, 2024
Via
Benzinga
Assessing ADMA Biologics: Insights From 4 Financial Analysts
August 12, 2024
Via
Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
September 05, 2024
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
Via
Investor's Business Daily
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
August 30, 2024
"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money down the road."
Via
Benzinga
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
August 29, 2024
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.
Via
Investor's Business Daily
Biohaven Stock Earns Relative Strength Rating Upgrade
August 21, 2024
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.
Via
Investor's Business Daily
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
August 21, 2024
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.
Via
Investor's Business Daily
Immunome Stock Sees RS Rating Jump To 91
August 20, 2024
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.
Via
Investor's Business Daily
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
August 19, 2024
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
August 19, 2024
Via
Benzinga
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
August 11, 2024
Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them?
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.